RWE 101 – How RWE is Being Used to Support the Treatment of Cancer
Real-world evidence (RWE) enhances cancer treatment through providing more comprehensive and personalized patient data. Here are summarized examples:
[1] Targeted Therapies for Lung Cancer: RWE aids in identifying actionable mutations in non-small-cell lung carcinoma (NSCLC), facilitating targeted treatments.
[2] Immuno-Oncology Treatments: Through studying melanoma patient responses to immune checkpoint inhibitors, RWE informs long-term safety, efficacy (effectiveness), and optimal usage.
[3] Treatment Adherence and Persistence: RWE helps determine factors affecting adherence to oral chemotherapies, enabling effective patient management.
[4] Clinical Trial Design: Real-world data can ensure clinical trial populations better reflect the real-world population’s diversity, increasing the trials’ relevance.
[5] Post-Market Surveillance: RWE allows monitoring of approved cancer drugs’ safety and effectiveness, identifying previously unknown adverse effects and comparing different treatments.
[6] Comparative Effectiveness Research: RWE can evaluate the benefits and harms of different treatments, such as drug classes or treatment methods, enhancing decision-making.
[7] Pediatric Oncology: RWE offers valuable insights into pediatric cancer treatment patterns and outcomes, critical given the ethical concerns with trials in pediatric populations.
[8] Health Economics and Outcomes Research: RWE assesses the cost-effectiveness of cancer treatments, informing coverage and reimbursement decisions.
[9] Precision Medicine: Real-world genomic data, combined with clinical outcomes, helps create more personalized treatment strategies, like using PARP inhibitors for BRCA-mutated ovarian cancer.
[10] Population Health Management: RWE can expose disparities in cancer care, prompting efforts to address these gaps.
In summary, RWE significantly contributes to cancer treatment. It complements clinical trials, supports personalized care, highlights patient voice, and improves overall cancer care quality. Despite data standardization and quality challenges, RWE’s potential to enhance cancer treatment remains vast.
Share this story...
Real World Evidence (RWE) 101 – Patient Retention
RWE 101 - Patient Retention Long-term Real-World Evidence (RWE) studies face significant challenges when it comes to patient retention, for several reasons:[1] Time Commitment: Participants in RWE studies are [...]
Real World Evidence (RWE) 101 – Patient Recruitment
RWE 101 - Patient Recruitment Real-world evidence (RWE) is health care information derived from real-world data (RWD). It can be generated through various study designs or analyses, including pragmatic [...]
Real World Evidence (RWE) 101 – HARPER
RWE 101 - HARPER Regulatory agencies, health technology assessors, and payers are increasingly interested in studies that make use of real-world data to inform regulatory and other policy or [...]
Real World Evidence (RWE) 101 – STaRT-RWE
RWE 101 - STaRT-RWE START-RWE (Structured Template for Planning and Reporting on the Implementation of Real World Evidence Studies) was developed to address the need for improved transparency and [...]
Real World Evidence (RWE) 101 – Protocol Design and ISPE GPP
RWE 101 - Protocol Design and ISPE GPP The International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Pharmacoepidemiology Practices (GPP) are a set of best practices for the conduct [...]
Real World Evidence (RWE) 101 – Protocol Design and Scientific Best Practices
RWE 101 - Protocol Design and Scientific Best Practices Designing a robust Real-World Evidence (RWE) study is crucial for generating reliable and valid insights that are acceptable to regulators. [...]
